Has Sumeet Mendonca, MD received payments from drug or device companies?

Yes. Drug and device makers reported $65,791 in general payments to Sumeet Mendonca, MD across 655 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sumeet Mendonca, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sumeet Mendonca, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sumeet Mendonca, MD

Medical Oncology · Gilbert, AZNPI 1518991223

Payments from drug & device makers

$65,791in general payments, 2019–2025

Across 655 payments — averaging $100.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$54K
Novartis$1K
Johnson & Johnson$915
AstraZeneca$838
Bristol Myers Squibb$637
Merck$619
plus $7K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	40	$54,085
Novartis	43	$1,317
Johnson & Johnson(2 entities)	68	$915
AstraZeneca(2 entities)	43	$838
Bristol Myers Squibb	40	$637
Merck	39	$619
AbbVie	35	$579
Daiichi Sankyo Inc.	23	$485
Rigel Pharmaceuticals, Inc.	18	$426
Pharmacyclics LLC, An Abbvie Company	18	$394
Amgen	20	$332
E.r. Squibb & Sons, L.L.C.	23	$314
Eisai Inc.	15	$300
Sanofi	15	$298
Seagen Inc.	18	$293
Regeneron Healthcare Solutions, Inc.	13	$291
Gilead(2 entities)	16	$269
Puma Biotechnology, Inc.	12	$259
Genentech USA, Inc.	12	$220
Incyte Corporation	11	$214
Takeda Pharmaceuticals U.S.A., Inc.	9	$189
EMD Serono, Inc.	7	$130
Karyopharm Therapeutics Inc.	5	$127
GSK	7	$126
Springworks Therapeutics, Inc.	5	$124
Astellas Pharma US Inc	6	$119
Blueprint Medicines Corporation	7	$115
Bayer	6	$114
AVEO Pharmaceuticals, Inc.	6	$111
Ipsen Biopharmaceuticals, Inc	6	$102
Beigene USA, Inc.	5	$100
Sanofi-aventis U.S. LLC	1	$100
Boehringer Ingelheim	5	$93
Lilly USA, LLC	5	$92
Intuitive Surgical	1	$90
Beone Medicines USA, Inc.	3	$70
Pharmacosmos Therapeutics Inc.	3	$66
Epizyme, Inc.	3	$65
Stemline Therapeutics Inc.	3	$55
Exelixis Inc.	2	$49
ADC Therapeutics America, Inc.	2	$45
Verastem, Inc.	3	$37
G1 Therapeutics, Inc.	2	$37
Adaptive Biotechnologies Corporation	2	$35
Tersera Therapeutics LLC	2	$35
Jazz Pharmaceuticals Inc.	2	$34
TG Therapeutics, Inc.	1	$32
Genmab U.S., Inc.	1	$28
Taiho Oncology, Inc.	2	$28
Mayne Pharma Commercial LLC	1	$27
Servier Pharmaceuticals LLC	1	$23
Array Biopharma Inc	2	$23
Sumitomo Pharma America, Inc.	1	$22
Deciphera Pharmaceuticals Inc.	1	$21
Kyowa Kirin, Inc.	1	$21
Caris MPI, Inc.	1	$21
Nestle Healthcare Nutrition Inc.	1	$19
Sobi, Inc	1	$19
Legend Biotech USA Inc.	1	$18
Clovis Oncology, Inc.	1	$17

How this compares

$65,791 in reported general payments places this provider in the 55th percentile of 59 medical oncology providers in Arizona.

See all medical oncology providers in Arizona →

Medicare billing

Part B allowed, 2024

$948,255

Medicare patients

718

Services billed

139,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Gilbert

Isaac BowmanGilbert$844K
Saba RadhiGilbert$540K
Zachary YeungGilbert$106K
Bryan WongGilbert$70K
Christina GomezGilbert$30K
Fade MahmoudGilbert$14K
Michael BookmanTucson$4.8M
Erkut BorazanciScottsdale$3.5M
Daniel von HoffScottsdale$2.5M
Jason SalganickPhoenix$1.6M

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →